Baycol – Alliance for Human Research Protection

October 7, 2012

America’s Healthcare Crisis–Part II–What Do We Get for $$$ ?

IV. What Do We Get for All That Money? According to the Kaiser Foundation:[1] The number of

America’s Healthcare Crisis–Part II–What Do We Get for $$$ ?

September 15, 2012

US Healthcare Third Leading Cause of Death_Barbara Starfield, MD

Is US Healthcare Really the best in the World? Starfield_JAMA_2000 The findings by Barbara Starfield, MD, of

US Healthcare Third Leading Cause of Death_Barbara Starfield, MD

August 20, 2012

Rx Drugs Recalled for Safety Issues from US market

FDA Drug Recall Due to Safety Issues 1980 – 2011 Drug Name: Approved Withdrawn Methaqualone

Rx Drugs Recalled for Safety Issues from US market

January 19, 2011

Lies, Damned Lies, and Medical Science

Is there something wrong with the scientific method in medical research? In 2005, Dr Ioannidis, a prominent,

Lies, Damned Lies, and Medical Science

March 31, 2010

FDA Approves Crestor Use for Healthy People–Watch Healthcare Costs Skyrocket

The New York Times reports that the FDA has approved the use of AstraZenceca’s statin, Crestor, for

FDA Approves Crestor Use for Healthy People–Watch Healthcare Costs Skyrocket

January 26, 2007

Bayer Settles Baycol AG Stuits $8 million

At least 100 people died because of the failure of Bayer to disclose thelethal risks of its

Bayer Settles Baycol AG Stuits $8 million

January 22, 2007

Role of Litigation in Defining Drug Risks_JAMA / BMJ

Below are excerpts from two timely articles that offer persuasive arguments backed by evidence demonstrating that litigation

Role of Litigation in Defining Drug Risks_JAMA / BMJ

November 23, 2006

Dangerous Deception: Hiding the Evidence of Adverse Drug Effects_NEJM

The drug industry's undue influence–on the FDA and its advisory committees that are made up mostly of

Dangerous Deception: Hiding the Evidence of Adverse Drug Effects_NEJM

October 26, 2006

Public Servant or Private Marketer? NIH Seeks Inquiry of Alzheimer’s researcher conflicts of interest

NIH: Public Servant or Private Marketer? NIH Seeks Outside Inquiry of Alzheimer’s researcher conflicts of interest –

Public Servant or Private Marketer? NIH Seeks Inquiry of Alzheimer’s researcher conflicts of interest

October 26, 2006

Bayer/ Baycol on Trial in Texas – NYT

Bayer/ Baycol on Trial in Texas_NYT Sat, 1 Mar 2003 Melody Peterson of the New York Times

Bayer/ Baycol on Trial in Texas – NYT

October 26, 2006

Cash Interests Taint Drug Advice – NATURE / Death a Risk of Antipsychotics – AP

Cash Interests Taint Drug Advice – NATURE / Death a Risk of Antipsychotics – AP Sun, 23

Cash Interests Taint Drug Advice – NATURE / Death a Risk of Antipsychotics – AP

October 26, 2006

Calls Mounting for FDA Revamp / Americans Are the most medicated population in the world – DHHS

October 26, 2006

NIH: Public Servant or Private Marketer?

NIH: Public Servant or Private Marketer? Wed, 22 Dec 2004 David Willman of the Los Angeles Times

NIH: Public Servant or Private Marketer?

October 26, 2006

FDA Underhanded Tactics Against Medical Officer Who Blew the Whistle

FDA Underhanded Tactics Against Medical Officer Who Blew the Whistle Mon, 29 Nov 2004 The Food and

FDA Underhanded Tactics Against Medical Officer Who Blew the Whistle

Load More Articles

ALLIANCE FOR HUMAN RESEARCH PROTECTION

America’s Healthcare Crisis–Part II–What Do We Get for $$$ ?

US Healthcare Third Leading Cause of Death_Barbara Starfield, MD

Rx Drugs Recalled for Safety Issues from US market

Lies, Damned Lies, and Medical Science

FDA Approves Crestor Use for Healthy People–Watch Healthcare Costs Skyrocket

Bayer Settles Baycol AG Stuits $8 million

Role of Litigation in Defining Drug Risks_JAMA / BMJ

Public Servant or Private Marketer? NIH Seeks Inquiry of Alzheimer’s researcher conflicts of interest

Bayer/ Baycol on Trial in Texas – NYT

Cash Interests Taint Drug Advice – NATURE / Death a Risk of Antipsychotics – AP

Calls Mounting for FDA Revamp / Americans Are the most medicated population in the world – DHHS

NIH: Public Servant or Private Marketer?

FDA Underhanded Tactics Against Medical Officer Who Blew the Whistle

Subscribe to Our Newsletter!